Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a bothering condition characterized by pain localized to the pelvic, perineal and/or genital area and lower urinary tract symptoms (LUTS). Phytotherapy, which involves the combination of two or more active compounds, can be used to treat this challenging condition. The aim of this study was to investigate the role of an oral combination of colostrum and Serenoa repens extracts (PROSTYM®) in the treatment of CP/CPPS patients. The main questions the present study aims to answer are: * Does PROSTYM® enhance quality of life of CPP/CPPS patients? * Does it help reducing pain symptoms of CPP/CPPS patients? Researchers will investigate whether PROSTYM® works to treat CPP/CPPS symptoms, so its efficacy, but also its tolerability and adherence to therapy. Participants will: * Take PROSTYM® every day for 6 months; * Visit the clinic for follow-up visits at 3 and 6 months; * Answer validated questionnaires and declare potential adverse events at follow-up visits.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
42
The composition of PROSTYM® (per capsule) includes bovine colostrum (30 mg), Serenoa extracts (320 mg), glutathione (30 mg), N-acetyl cysteine (20 mg), Ribes nigrum extracts (50 mg), willow extracts (50 mg), zinc (5 mg), selenium (27.5 micrograms), and vitamin E (6 mg). Drug administration (1 capsule per day) for 6 months.
Molinette Hospital
Torino, Torino, Italy
Rate of ≥25% Decrease in CPSI Total Score Compared to Baseline
improvement of CP symptoms
Time frame: 6 months
Rate of ≥25% Decrease in CPSI Pain Domain Score Compared to Baseline
improvement of CP pain symptoms
Time frame: 6 months
Rate of ≥25% Decrease in CPSI QoL Domain Score Compared to Baseline
improvement of CP QoL
Time frame: 6 months
Total Number of Adverse Events
number and type, so safety analysis
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.